May 19, 2020
View this post on Instagram

Meet Chandra Ramanathan, Global Head, Pharma R&D Open Innovation, Bayer. ⠀⠀⠀⠀⠀⠀⠀⠀⠀ ➖How has the COVID-19 pandemic changed the way we look at pharmaceutical companies? The COVID-19 crisis has shown us much about our society, not the least of which is exactly how critical health and nutrition are, in times both normal and extraordinary. This experience has given new importance to Bayer’s vision: “Health for all, hunger for none.” And in order to achieve this vision, we have truly showcased our flexibility as a company and an industry, changing the way in which we work, on multiple levels, throughout our sites. I also believe that this pandemic has highlighted to our society the importance of collaboration. This crisis has presented challenges that individual companies cannot fix. As a result, biotech companies are now partnering with the government to make new public/private partnerships which will help get us the vaccines and therapies needed now and for a healthier future. ⠀⠀⠀⠀⠀⠀⠀⠀⠀ ➖Why is Kendall Square still such a valuable location for an international pharmaceutical company like Bayer? The reasons for Bayer’s presence in Kendall are just as compelling now as they were prior to the COVID-19 pandemic. The intellectual capital and entrepreneurial spirit of this community, as well as the power of its advocates like Kendall Square Association and MassBio, as well as the strong network of hospitals, reinforces our mission and our need to build a healthier, global future. This area is unlike any other in the United States, and its unique qualities make it a great addition to the list of communities Bayer calls home. ⠀⠀⠀⠀⠀⠀⠀⠀⠀ Continue ⬇️ #kendallcollective

A post shared by Kendall Square Association (@ksq_association) on